Stock Analysis
3 Swedish Growth Companies With Up To 30% Insider Ownership
Reviewed by Simply Wall St
As global markets navigate through a period of heightened volatility and mixed economic signals, Sweden's stock market has shown resilience, with key indices maintaining stability. In this environment, identifying growth companies with substantial insider ownership can provide investors with confidence in the alignment of interests between shareholders and management. In this article, we explore three Swedish growth companies where insider ownership reaches up to 30%, highlighting their potential for long-term value creation amidst current market conditions.
Top 10 Growth Companies With High Insider Ownership In Sweden
| Name | Insider Ownership | Earnings Growth |
| CTT Systems (OM:CTT) | 16.9% | 24.8% |
| Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
| Biovica International (OM:BIOVIC B) | 18.8% | 73.8% |
| Yubico (OM:YUBICO) | 37.5% | 43.8% |
| BioArctic (OM:BIOA B) | 34% | 104.2% |
| KebNi (OM:KEBNI B) | 37.8% | 90.4% |
| InCoax Networks (OM:INCOAX) | 18.1% | 104.9% |
| Calliditas Therapeutics (OM:CALTX) | 12.7% | 53.7% |
| SaveLend Group (OM:YIELD) | 23.3% | 103.4% |
| edyoutec (NGM:EDYOU) | 13.4% | 63.1% |
We're going to check out a few of the best picks from our screener tool.
Calliditas Therapeutics (OM:CALTX)
Simply Wall St Growth Rating: ★★★★★★
Overview: Calliditas Therapeutics AB (publ) is a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for orphan indications in renal and hepatic diseases, with a market cap of SEK11.17 billion.
Operations: The company generates revenue primarily through its pharmaceuticals segment, which amounted to SEK1.31 billion.
Insider Ownership: 12.7%
Calliditas Therapeutics, a growth company with high insider ownership in Sweden, recently reported Q2 2024 sales of SEK 559.78 million, nearly doubling from last year. Despite a net loss reduction to SEK 47.48 million, the company received full EU marketing authorization for Kinpeygo and met primary endpoints in its Phase 2b TRANSFORM trial for setanaxib. The Asahi Kasei acquisition offer highlights strong insider confidence and potential strategic benefits for Calliditas' innovative therapies.
- Dive into the specifics of Calliditas Therapeutics here with our thorough growth forecast report.
- Insights from our recent valuation report point to the potential undervaluation of Calliditas Therapeutics shares in the market.
EQT (OM:EQT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: EQT AB (publ) is a global private equity firm specializing in private capital and real asset segments, with a market cap of SEK378.27 billion.
Operations: Revenue segments (in millions of €): Central: 37.20, Real Assets: 878.70, Private Capital: 1284.90
Insider Ownership: 31%
EQT AB, a growth company with high insider ownership in Sweden, has been active in M&A discussions, including potential bids for Compass Education and JB Chemicals. Despite losing out on Aavas Financiers to CVC Capital Partners, EQT continues its strategic pursuits. The firm reported significant earnings growth of EUR 282 million for H1 2024 and initiated a share repurchase program to optimize capital structure. Analysts forecast robust revenue and earnings growth above market averages over the next three years.
- Take a closer look at EQT's potential here in our earnings growth report.
- The valuation report we've compiled suggests that EQT's current price could be inflated.
AB Sagax (OM:SAGA A)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AB Sagax (publ) is a property company operating in Sweden, Finland, France, Benelux, Spain, Germany, and other European countries with a market cap of SEK94.73 billion.
Operations: AB Sagax generates SEK4.63 billion in revenue from its real estate rental segment across various European markets.
Insider Ownership: 28.6%
AB Sagax, a Swedish real estate firm, forecasts earnings growth of 30.7% annually, outpacing the market average. Despite recent shareholder dilution and debt concerns, the company reported substantial revenue and net income increases for Q2 2024. Revenue reached SEK 1.20 billion while net income soared to SEK 978 million from SEK 53 million year-over-year. Sagax also completed a €500 million green bond offering to support its growth and sustainability initiatives.
- Get an in-depth perspective on AB Sagax's performance by reading our analyst estimates report here.
- In light of our recent valuation report, it seems possible that AB Sagax is trading beyond its estimated value.
Taking Advantage
- Get an in-depth perspective on all 88 Fast Growing Swedish Companies With High Insider Ownership by using our screener here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OM:CALTX
Calliditas Therapeutics
A commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
